Related Experiment Video

Updated: Sep 5, 2025

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.3K

Dimethyl Fumarate as Therapeutic Alternative in Moderate-to-Severe Psoriasis: Our Experience

Pau Rosés Gibert1, Francisco Javier de la Torre Gomar1, Amaia Saenz Aguirre1

  • 1Dermatology Department, Araba University Hospital, Vitoria-Gasteiz, Spain.

Psoriasis (Auckland, N.Z.)
|July 6, 2022
PubMed
Abstract

Insights

Dimethyl fumarate (DMF) effectively treats moderate-to-severe psoriasis in adults. This study shows significant PASI and BSA score reductions with manageable side effects, indicating DMF

Area of Science:

  • Dermatology
  • Pharmacology

Background:

  • Dimethyl fumarate (DMF) is an approved oral therapy for moderate-to-severe psoriasis requiring systemic treatment.
  • Psoriasis is a chronic autoimmune disease affecting skin, characterized by red, itchy, scaly patches.

Purpose of the Study:

  • To evaluate the clinical experience and treatment outcomes of dimethyl fumarate (DMF) in adult patients with moderate-to-severe psoriasis in Spain.
  • Assess the efficacy and safety profile of DMF for psoriasis management.

Main Methods:

  • Retrospective study of 30 adult patients with moderate-to-severe psoriasis treated with DMF.
  • Treatment duration ranged from 4 to 55 weeks, with a median of 15 weeks.
  • Evaluated Psoriasis Area and Severity Index (PASI) and Body Surface Area (BSA) scores, and documented adverse events (AEs).

Main Results:

  • Significant reductions in PASI and BSA scores observed by week 24.
  • At week 36, 5 patients achieved PASI and BSA scores of 0.
  • Most frequent adverse events included diarrhea (40.0%), flushing (13.3%), and lymphopenia (3.3%); 47.1% of AEs were managed by dose adjustment. Treatment discontinuation due to AEs occurred in 43.3% of patients.

Conclusions:

  • Dimethyl fumarate (DMF) demonstrates efficacy in reducing psoriasis severity.
  • DMF is a potentially safe and effective treatment option for adult patients with moderate-to-severe psoriasis.
  • Adverse event management through dose adjustment is feasible, though discontinuation rates due to AEs should be considered.
Keywords:
clinical experiencedimethyl fumaratemoderate-to-severe psoriasisretrospective study

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.0K
Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice04:47

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice

Published on: October 27, 2023

1.2K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
260
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
230
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
198
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
176
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
440